Povidone
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Povidone: From Dry Eye Syndrome to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Povidone is a hydrophilic polymer used as a lubricant in ocular formulations, originally for dry eye syndrome and xerophthalmia. The TxGNN model predicts it may be effective for Congenital Ichthyosiform Erythroderma, but currently 0 clinical trials and 0 publications support this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dry eye syndrome, xerophthalmia |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, povidone is a hydrophilic polymer used as a lubricant, humectant and film-forming agent in ocular formulations. Its efficacy in dry eye has been the basis of its use, and mechanistically it may be applicable to dry, scaly skin conditions.
A plausible but unverified rationale is that its moisture-retaining and film-forming properties could act as an emollient or barrier-supporting agent for the hyperkeratotic, dry and scaly skin of congenital ichthyosiform erythroderma. This hypothesis is speculative.
Congenital ichthyosiform erythroderma is a genetic keratinization disorder (for example, mutations in TGM1, ALOXE3 or ALOX12B). Moisturizers do not address the root cause, so any benefit would be symptomatic at best. A high prediction score alone is not evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M018 (cancelled) | iVIZIA Dry Eye | Solution/drops | Not specified |
Other dosage forms recorded for povidone include a topical gel and a liquid.
Safety Considerations
- Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not from label text): epilepsy, liver disease, gallbladder disease, respiratory failure, atrioventricular dissociation, atrioventricular block, and heart block. These should be verified against official labeling before any interpretation.
No drug interaction records were found.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials or publications (Evidence Level L5). The only US authorization on record is cancelled, and the proposed mechanism is speculative and symptomatic at best for a genetic keratinization disorder.
To proceed, the following is needed:
- Official package insert warnings and contraindications (currently a blocking gap for safety screening)
- Detailed mechanism of action data
- Preclinical or clinical evidence of benefit in congenital ichthyosiform erythroderma
- Assessment of topical route and formulation compatibility
- Review of the knowledge-graph contraindication signals against labeling
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.